NCT06241846
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Recruiting · Phase 2 · MediLink Therapeutics (Suzhou) Co., Ltd. · registry updated 2025-08-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
Inclusion
- Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
- Age ≥ 18 years.
- Patients should meet the following conditions to be enrolled:
- Histologically or cytologically confirmed prostate cancer. Note: The primary histological classification indicated by biopsy should be adenocarcinoma;
- Meeting the following criteria for clinical diagnosis of mCRPC:
- Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
Exclusion
- Previously treated with drugs targeting B7H3.
- Currently participating in another clinical study, unless it is an observational (non-interventional) clinical study, or the patient is at the follow-up period of an interventional study.
- Previously treated with topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
- The washout period of the previous anti-tumor therapy is considered insufficient.
- Patients received major surgery.
- Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation.